[Sensitivity of screening kits for anti-HIV antibodies. 1999 update. Retrovirus Working Group of the French Society for Blood Transfusion].
A comparative evaluation of the sensitivity of anti-HIV screening assays has been recently performed with a selected panel of 65 samples which included HIV1 group M (per-seroconversions, seroconversions and seropositives infected with genotypes A, B, C, D, E), HIV1 group O and HIV2. The results obtained with the 21 ELISA HIV1 + HIV2 screening assays are presented. Among these 21 assays, four are combined anti-HIV and p24 Ag assays. All the assays except four fulfilled the criteria defined at the beginning of the study, i.e., positive results on all the seropositives including seroconversions and positive results on at least 50% of the per-seroconversions. The main differences were observed with the ten per-seroconversion samples, the number of positive results on such samples varying from three to ten. The constant improvement of anti-HIV screening tests which leads one to shorten the 'window' period permits and earlier diagnosis of HIV infection and a progressive decrease of the transfusional risk.
Couroucé
A M
AM
Institut national de la transfusion sanguine, Paris, France.
D015492:AIDS Serodiagnosis; D004797:Enzyme-Linked Immunosorbent Assay; D005069:Evaluation Studies as Topic; D015483:HIV Antibodies / Q000097:blood*; D016655:HIV Core Protein p24 / Q000097:blood; D006679:HIV Seropositivity / Q000276:immunology; D015497:HIV-1 / Q000145:classification / Q000235:genetics / Q000276:immunology; D015498:HIV-2 / Q000145:classification / Q000235:genetics / Q000276:immunology; D006801:Humans; D008403:Mass Screening / Q000379:methods*; D011933:Reagent Kits, Diagnostic; D012306:Risk; D012680:Sensitivity and Specificity; D065227:Transfusion Reaction
D015483:HIV Antibodies; D016655:HIV Core Protein p24; D011933:Reagent Kits, Diagnostic